Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1600 1633 1653 1699 1797
This examiner grants 60% of resolved cases
Alyssa G. Weston is a patent examiner assigned to Art Unit 1600 within Tech Center 1700. The examiner's professional record includes 111 resolved cases. The data indicates an allowance rate of 59.5% for these applications. This figure serves as a primary indicator of the probability of success for cases on this docket. Additionally, the median days to allowance is 1276, which establishes a specific timeframe for the prosecution process. These metrics offer a foundational understanding of the examiner's approach to patent applications.
The interview lift for this examiner is 51.9%. This 51.9% lift shows the change in the likelihood of allowance when an interview is conducted compared to the 59.5% base rate. With 111 resolved cases, the data provides a view of the examiner's historical performance. The 1276-day median pendency is a key metric for managing client expectations regarding the duration of the patent application process in Tech Center 1700. Practitioners should evaluate the allowance rate and the interview lift to determine the most effective strategy for their specific cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18626460 | RECRUITMENT METHODS AND COMPOUNDS, COMPOSITIONS AND SYSTEMS FOR RECRUITMENT | Final Rejection | Pairwise Plants Services, Inc. |
| 18382626 | CD47 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE OCULAR DISEASES | Final Rejection | President and Fellows of Harvard College |
| 18576909 | METHODS FOR DIFFERENTIATING AND SCREENING STEM CELLS | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 19353469 | COMPOSITIONS, DEVICES, AND METHODS RELATING TO USE OF AN AMNIOTIC MEMBRANE FETAL TISSUE PRODUCT | Final Rejection | BioTissue Holdings Inc. |
| 18561889 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED GRANULOCYTE-MACROPHAGE PROGENITORS FOR CANCER IMMUNOTHERAPY | Non-Final OA | University of Southern California |
| 17784935 | ENGINEERED IMMUNE CELLS WITH REDUCED TOXICITY AND USES THEREOF | Final Rejection | The General Hospital Corporation |
| 18006446 | METHOD FOR PRODUCING CULTURED MEAT ON BASIS OF CELL SHEET COATING TECHNIQUE, AND CULTURED MEAT PRODUCED THEREBY | Non-Final OA | Industry-Academic Cooperation Foundation, Yonsei University |
| 18266712 | TAU BIOSENSOR CELL LINES | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 17760245 | CYTOTOXIC T CELLS DERIVED FROM HUMAN T CELL-DERIVED IPS CELLS | Final Rejection | THE UNIVERSITY OF TOKYO |
| 18949699 | COMPOSITIONS AND MATERIALS FOR REGENERATION OF SKELETAL MUSCLE | Non-Final OA | Purdue Research Foundation |
| 17928674 | COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC ANTIGENS USING CRISPR-BASED BASE EDITOR SYSTEMS | Final Rejection | The Trustees of Columbia University in the City of New York |
| 18003705 | ENGINEERED MULTICELLULAR ORGANISMS | Final Rejection | University of Vermont and State Agricultural College |
| 18517066 | METHOD FOR INDUCING AND DETECTING SOLUBLE LOX-1 (sLOX-1) IN CULTURED BLOOD CLOTS | Non-Final OA | GEORGE MASON UNIVERSITY |
| 17602277 | METHODS AND COMPOSITIONS FOR PROGRAMMING T CELL DIFFERENTIATION AND ENHANCING T CELL PROLIFERATION | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18347279 | MULTI-LAYER AMNION PRODUCT, RELATED DEVICES, AND RELATED METHODS | Final Rejection | Axogen Corporation |
| 18792799 | METHOD FOR ENHANCING THE SUPPRESSIVE PROPERTIES OF TREG CELLS | Non-Final OA | UCL BUSINESS LTD. |
| 17053752 | MESENCHYMAL STROMAL CELL EXOSOME-TREATED MONOCYTES AND USES THEREOF | Non-Final OA | Children's Medical Center Corporation |
| 18971862 | IMMUNOSUPPRESSIVE ANTIGEN-SPECIFIC CHIMERIC ANTIGEN RECEPTOR TREG CELLS FOR PREVENTION AND/OR TREATMENT OF AUTOIMMUNE AND ALLOIMMUNE DISORDERS | Non-Final OA | The University of Toledo |
| 18931782 | Immunosuppressive Antigen-Specific Chimeric Antigen Receptor Treg Cells for Prevention and/or Treatment of Autoimmune and Alloimmune Disorders | Non-Final OA | The University of Toledo |
| 18938929 | QUALITY CONTROL METHODS FOR AUTOMATED CELL PROCESSING | Non-Final OA | LONZA WALKERSVILLE, INC. |
| 18323196 | QUALITY CONTROL SUBSTANCE USED IN URINE SEDIMENT ANALYZER | Final Rejection | ARKRAY, Inc. |
| 18731629 | ORGANOIDS RELATED TO IMMUNOTHERAPY AND METHODS OF PREPARING AND USING THE SAME | Non-Final OA | Wake Forest University Health Sciences |
| 18249418 | GENERATION OF CD4+ EFFECTOR AND REGULATORY T CELLS FROM HUMAN PLURIPOTENT STEM CELLS | Final Rejection | Sangamo Therapeutics, Inc. |
| 17912480 | ISCHEMIC HEART DISEASE ANIMAL MODEL USING 3-DIMENSIONAL BIOPRINTED OCCLUDE, AND MANUFACTURING METHOD THEREFOR | Non-Final OA | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY |
| 18571568 | METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION | Final Rejection | Megakaryon Corporation |
| 18037478 | EXTRACELLULAR VESICLES DERIVED FROM CARDIOSPHERE-DERIVED CELLS AS ANTI-SHOCK THERAPEUTICS | Final Rejection | Tiffani C. Chance |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy